fda warning letters glp-1 october 2025 issued 30 to telehealth companies for false and misleading claims about compounded products. This marks the second round of enforcement action since the agency's September crackdown on misleading The FDA sent a warning

GLP-1 receptor agonists, which mimic the hormone Glucagon-Like Peptide-1, are transforming treatment for diabetes and obesity

For food and beverage companies, understanding how their use might evolve will be critical to staying relevant, from reformulating products to meeting new nutritional needs

This is why variety in your prep is so important

A new FDA-approved obesity pill could offer a lower-cost alternative to injectable GLP-1 drugs like Ozempic and Mounjaro

You may still be a candidate for the Fitish Microdosing program, a lower dose option for patients outside the standard BMI range who want a gentler, cosmetic approach

p=0.030) and 25% higher at 12 months (95% CI: 2 to 59